Published in Hepatitis Weekly, August 11th, 2003
These licenses will allow Baxter to continue to enhance and develop its own large-scale plasma-testing technology for screening plasma. The financial terms and other details of the license were not disclosed.
"This license represents the first usage of Chiron's intellectual property in plasma fractionation," said William G. Green, Esq., Chiron's general counsel....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.